INTRODUCTION
Non-Alcoholic Fatty Liver Disease (NAFLD) comprises a spectrum of pathologic lesions that ranges from hepatic steatosis to a form of fatty liver hepatitis known as non-alcoholic steatohepatitis (NASH). Histologic features independently associated with the diagnosis of NASH in human biopsies include hepatic steatosis, hepatocyte ballooning, lobular inflammation, Mallory's hyaline and perisinusoidal fibrosis. Moreover, NASH has the potential to advance to cirrhosis requiring liver transplant (Abdelmalek et al., 1995; Caldwell and Hespenheide, 2002; Charlton et al., 2001; Powell et al., 1990) . A recent overview of clinical data estimates that NAFLD and NASH affect 17-33% and 5.7-17% of American adults, respectively. Although the etiology of NASH is not completely understood, most investigators agree that a critical baseline of steatosis requires a second "hit" of oxidative stress that promotes the subsequent inflammation and fibrosis of NASH. NAFLD is primarily associated with features of the metabolic syndrome, including obesity, diabetes, dyslipidemia, and insulin resistance (McCullough, 2006) . Importantly, these NAFLD-associated features invariably require pharmacologic intervention with one or more therapeutic agents. It therefore follows that a significant portion of the NAFLD demographic is already using prescription medication.
In the present study, NAFLD was recapitulated in two of its prominent forms, simple fatty liver (SFL) and NASH, respectively. The SFL model utilized a highfat (HF) diet, while the NASH model utilized a methionine-, choline-deficient (MCD) diet. The histologic changes that occur in the MCD model have been thoroughly characterized and determined to be remarkably similar to those seen in human NASH (George et al., 2003) . Histologic features of NASH necessarily include hepatic steatosis, mild, lobular inflammatory infiltration, and hepatocellular ballooning degeneration (Brunt and Tiniakos, 2005a) .
Because the vast majority of drug metabolism occurs in the liver, it is particularly important to understand the transport processes involved in the elimination of drug metabolites formed in the organ, especially a diseased one. In the liver, there are two basic types of transporters. These include the uptake transporters, e.g. Organic anion-transporting polypeptides (Oatps) and Organic cation transporters (Octs), which facilitate the extraction of drugs from portal blood into hepatocytes, and the efflux transporters, e.g. Multidrug resistance-associated proteins (Mrps), Bile salt excretory protein (Bsep) and Breast cancer resistance protein (Bcrp), which extrude their substrates out of hepatocytes into bile or blood. While not all drugs require uptake transport to cross the sinusoidal membrane into hepatocytes, virtually all of their metabolites require efflux transporters in order to be excreted into bile and blood for biliary and urinary elimination, respectively. 
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8 glucuronic acid (GLUC) to form APAP-SULF and APAP-GLUC, respectively (Moldeus, 1978; Grafstrom et al., 1979) . A small portion of a dose of APAP will undergo cytochrome P450 metabolism to the reactive metabolite N-acetyl-pbenzoquinoneimine (NAPQI), which is subsequently conjugated with glutathione (GSH) to form APAP-GSH. In rats, excretion of APAP-GLUC and APAP-GSH metabolites from the liver occurs predominantly via the biliary route, whereas the APAP-SULF metabolite predominantly undergoes sinusoidal efflux and subsequent elimination in the urine (Gregus et al., 1988c) . Importantly, all APAP metabolites require efflux transport in order to be excreted from the liver, and each can be detected in both bile and urine (Chen et al., 2003b; Gregus et al., 1988b; Xiong et al., 2002b; Zamek-Gliszczynski et al., 2006a; Manautou et al., 2005b) .
In vivo disposition studies and in vitro functional transport experiments indicate Mrp2, Mrp3, Mrp4 and Bcrp each have the ability to transport a variety of unconjugated and conjugated drugs, including APAP metabolites (Buchler et al., 1996; Nakanishi et al., 2003; Xiong et al., 2000; ZamekGliszczynski et al., 2005a; Zamek-Gliszczynski et al., 2006b) . It is important to emphasize the distinctive location of these four transporters in hepatocytes, as well as their respective APAP metabolite substrates. Mrp2 and Bcrp are localized to the canalicular (apical) membrane of hepatocytes from which they excrete their substrates into the bile canaliculi. Accordingly, in a healthy liver, biliary excretion of the SULF, GLUC and GSH conjugates of APAP is predominantly DMD #15107 9 mediated by Mrp2, while Bcrp appears also to contribute to excretion of APAP-SULF conjugates (Borst et al., 2000; Buchler, Konig, Brom, Kartenbeck, Spring, Horie, and Keppler, 1996; Chen et al., 2003a; Keppler and Konig, 1997; Zamek-Gliszczynski et al., 2005b) . Mrp3 and Mrp4 are expressed at the sinusoidal (basolateral) membrane of hepatocytes and cholangiocytes from which they expel their substrates into the blood (Konig et al., 1999; Donner and Keppler, 2001; Soroka et al., 2001) . Sinusoidal excretion of the APAP-GLUC metabolite from hepatocytes is predominantly mediated by Mrp3, while Mrp4 appears to mediate excretion of APAP-SULF metabolites (Chen et al., 2001; Zamek-Gliszczynski et al., 2006d; Manautou et al., 2005a) .
Recent studies indicate that Mrp3 and Mrp4 have an equal role in the efflux of APAP-SULF (Zamek-Gliszczynski et al., 2006c) .
During other liver disease states such as septic cholestasis, extrahepatic cholestasis and alcoholic and viral hepatitis, human and rodent studies have demonstrated alterations in cytochrome P450-mediated drug metabolism, transport and pharmacokinetics (Congiu et al., 2002; Farrell et al., 1978; Farrell et al., 1979; Figg et al., 1995; Forrest et al., 1977; Kubitz et al., 1999; Nadai et al., 2001; Narang et al., 1985; Narang et al., 1982; Narang et al., 1981; Westphal and Brogard, 1997) . However, there is little information on the effect of NAFLD on these same parameters. Therefore, the purpose of the present study was to determine the effect of NAFLD on efflux transporter expression in liver, as well as disposition of APAP metabolites. (Howie et al., 1977a; Chen et al., 2000; Slitt et al., 2003d) . APAP and its metabolites were resolved using a Zorbmax SB-C 18 reverse-phase 4.6-mm x 25-cm column with a Phenomenex Security Guard Column Guard and eluted using a mobile phase composed of 12.5% HPLC-grade methanol, 1% acetic acid, and 86.5% water, run isocratically at a flow rate of 1.2 mL/minute. concentrations of APAP and its metabolites were calculated using an APAP standard curve since the molar extinction coefficients of APAP and its conjugated metabolites are approximately the same (Howie et al., 1977b) . To precipitate proteins in bile, plasma, and urine, samples were diluted 1:2, 1:2, and 1:3, respectively, with ice-cold methanol and centrifuged at 4,000 x g for 30 minutes
METHODS

Materials
at 4°C Oligonucleotides with a high degree of similarity (≥80%) to other rat gene transcripts were excluded from the design.
Total RNA (1 µg/µL; 10 µL/well) was added to each well of a 96-well plate containing capture hybridization buffer and 50 µL of each diluted probe set. For each gene, total RNA was allowed to hybridize to the probe set overnight at 53°C.
Subsequent hybridization and quantitation steps were performed according to the manufacturer's protocol (QuantiGene Reagent System, Panomics; Fremont, CA).
Western Blot Analysis of Mrp2, Mrp3, Mrp4 and Bcrp Protein Expression.
Liver crude membrane preparations were made as described previously (Slitt et al., 2003c) . Liver and kidney protein concentrations were determined using the Statistics. For excretion studies, statistical differences between diet groups at each time point were determined using a one-way analysis of variance followed by a Duncan's Multiple Range post hoc test. For mRNA and protein expression analyses, statistical differences between diet groups were also determined using 
RESULTS
Liver histology. Figure 1 demonstrates the effect of the respective high-fat and MCD diets on liver histology after 8 weeks. Hepatic steatosis was apparent at 2 weeks in rats fed the MCD diet but not in rats fed the control standard diet.
Notably, inflammation and fibrosis were plainly absent in the MCD group at this early time-point (data not shown). However, following 8 weeks on the diet, feeding on the respective high-fat and MCD diets have on efflux transporter mRNA levels in liver. In high-fat rats, Mrp5 mRNA levels were increased 350%, whereas Mrp6 and Bsep were each decreased by 50%. Mrp1-4 and Bcrp mRNA levels were unchanged in livers of high-fat rats. In MCD rats, Mrp3, Mrp4 and Bcrp mRNA expression levels were increased 2990%, 405% and 59%, respectively. Mrp1 and Mrp2 mRNA levels were not altered by the high-fat or MCD diet.
Efflux transporter protein levels in liver following 8 weeks of feeding on the respective high-fat and MCD diets. Figure 3 shows the effect of the respective high-fat and MCD diets on Mrp2, Mrp3, Mrp4 and Bcrp protein levels in liver. In MCD rats, Mrp2, Mrp3, Mrp4 and Bcrp protein expression levels were increased 185%, 253%, 246% and 71%, respectively. Notably, no changes in protein levels of the major APAP metabolite transporters were observed in the livers of high-fat rats.
Effect of high-fat and MCD diets on bile flow. Figure 4 shows the cumulative amount of bile collected during the 90 minutes following APAP administration for control, high-fat and MCD rats. The cumulative bile volume in high-fat rats was significantly greater than the control by 19% at 60 minutes and 26% at 90 minutes. MCD rat bile flow did not differ from the control. Importantly, the data from these models of NAFLD do not indicate impairment of bile secretory function.
This article has not been copyedited and formatted. The final version may differ from this version. The biliary concentration of each major metabolite of APAP was recurrently observed to be significantly decreased in MCD rats relative to control and highfat rats. In contrast to APAP parent, each of these metabolites, i.e. APAP-GLUC, APAP-GSH and APAP-SULF, does require active transport in order to be excreted from hepatocytes. minutes, the plasma concentration of APAP-SULF in MCD rats was significantly lower than the control group by an average of 50%.
Effect of high-fat and MCD diets on urinary excretion of APAP and APAP metabolites. Figure 8 shows the concentration of APAP and its metabolites in
This article has not been copyedited and formatted. The final version may differ from this version. concentration of metabolites between control, high-fat and MCD rats. However, the concentration of the APAP-GLUC metabolite was 80% higher in the urine of MCD rats compared to the control. Importantly, this same metabolite was elevated in the plasma of MCD rats throughout the 90-minute time-course.
APAP-GSH was not detected in the urine of any group.
This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
The current study presents novel data that demonstrates the effects of experimental NAFLD on transporter expression and drug disposition. The clinical relevance of these topics is underscored by the fact that the NAFLD patient population, a demographic that uses a great quantity and variety of prescription medications, is expected to continue growing at an alarming rate (Kopelman, 2000; Brunt and Tiniakos, 2005b) . In order to expand our comprehension and/or potentially develop pharmacologic treatment for this disorder, extensive study of accurate animal models will serve as an invaluable tool. It is thus pertinent to note that the current models of NAFLD (i.e. high-fat and MCD diets) provided accurate histologic representations of simple fatty liver (SFL) and non-alcoholic steatohepatitis (NASH), respectively.
It is important to note that there were no alterations in bile flow between the control and modified diet groups. The cumulative bile flow was significantly elevated in high-fat rats but only at the later time-points. These are each a contrast to the obese Zucker rat (a model of insulin resistance and obesity) in which bile secretory function in fatty liver is impaired, nonetheless in the absence of cholestatic injury (Pizarro et al., 2004a; Geier et al., 2005) . This is the first study to examine liver efflux transporter expression in a high-fat and MCD dietary models of simple hepatic steatosis and NASH in rats. Both models resulted in multiple alterations in liver and kidney expression of efflux transporters. It is interesting to note that, when the mRNA levels of a given efflux transporter were altered in the high-fat diet, the MCD model generally generated the same effect (i.e. increased Mrp5 in liver and kidney; decreased Mrp6 in liver and kidney). In contrast, only MCD rats were characterized by up-regulation of mRNA and protein levels of the hepatic efflux transporters Mrp2, 3, 4 and Bcrp.
The obvious alterations in transporter expression and drug disposition in the current study encourage further investigation into mechanisms of transcriptional regulation during NAFLD, such that would likely provide greater insight into necessary differences at the molecular level between simple fatty liver and steatohepatitis in rats. It is useful to note that, at the histologic level, the major principal difference between the high-fat and MCD rats was the presence of inflammatory infiltrates and fibrosis in MCD rat livers. Thus, one important factor to consider with regard to efflux transporter regulation during NAFLD is the role of pro-inflammatory cytokines. Elevated levels of the pro-inflammatory cytokines Tumor necrosis factor (Tnf)-α and Interleukin (IL)-6 have been detected in the plasma of biopsy-proven NASH patients but not in patients with simple hepatic steatosis (Abiru et al., 2006; Kugelmas et al., 2003; Bahcecioglu et al., 2005) .
Consistent with the current model, the early stages of MCD-induced NASH are characterized by up-regulation of hepatic IL-6 mRNA and elevated plasma levels of Tnf-α (Chawla et al., 1998; Starkel et al., 2003) . While there is little information on the role of IL-6 in the regulation of hepatic transporters in rats, the role of Tnf-α in this case has been well-studied utilizing the endotoxin-induced model of sepsis (Whiting et al., 1995; Green et al., 1996; Geier et al., 2003b; Cherrington et al., 2004) . Specifically, down-regulation of Mrp2 mRNA during endotoxemia has been demonstrated to be dependent on Tnf-α (Geier et al., 2003a) . In contrast, in obese Zucker rats, which develop elevated plasma levels of Tnf-α, abrogation of Tnf-α activity with etanercept has no effect on Mrp2 protein levels (Liu et al., 2002; Pizarro et al., 2004b) . While there is limited data on the hepatic and serum levels of pro-inflammatory cytokines in rat models of NAFLD, it seems reasonable to propose that cytokines may be important in transporter regulation in the MCD model of NASH.
Importantly, the biochemical mechanisms by which the high-fat and MCD diets induce their respective pathologies in the liver are markedly distinct. Thus, direct comparison of the effects, e.g. gene expression, between the high-fat and MCD groups was deemed inappropriate for statistical analysis in these studies. In the high-fat dietary model, induction of hepatic steatosis is most likely a consequence of increased net flux of lipids through the liver. In contrast, the MCD model achieves its histologic recapitulation of NASH via a series of events consistent with lipid peroxidation as a pathogenic mechanism for initiation and perpetuation of liver injury, inflammatory recruitment, stellate cell activation and fibrogenesis (George et al., 2003) . While the initial steatosis of the MCD model is not associated with the peripheral insulin resistance that is frequently observed in human NASH, the consequent damage, including hepatocellular injury, 
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26 inflammatory recruitment and zone 3 fibrosis does resemble that observed in human NASH (George et al., 2003) .
It is pertinent to note that the difference between the "control" and MCD diets utilized in the current study was not exclusive to the presence or absence of methionine and choline. An arguably more appropriate dietary control would be achieved by merely re-supplementing the MCD diet with methionine and choline.
Nonetheless, both diets applied in the current study are, in fact, fully defined in terms of their amino acid content, and it is thus known that the "control" diet (Teklad 7001 4% Mouse/Rat Diet) is methionine and choline sufficient, resulting in a histology reflective of a healthy liver (Figure 1 ). At the same time, there is no question that the methionine and choline deficiency is responsible for the pathology observed ( Figure 1F ). However, it is not entirely clear whether the alterations in transporter expression (and thus APAP-GLUC metabolite excretion)
are the consequence of a chronic dietary deficiency in methionine and choline, or, conversely, a regulatory response to the progressive damage and/or steatosis that occur as a result of the deficiency. According to the mRNA and histologic analysis of control and MCD rat livers following 2 week of the respective diets, acute biochemical deficiency of methionine and choline is clearly not responsible for inducing alterations in transporter expression.
The latter part of the current study examined the disposition of acetaminophen metabolites during NAFLD. In high-fat rats, there were no significant differences in the concentration of APAP metabolites in the plasma or urine and relatively few differences in the biliary excretion of metabolites. It is therefore apparent that simple hepatic steatosis has no discernible effect on the disposition of APAP metabolites. In contrast, there were obvious alterations in the disposition of the APAP-GLUC, APAP-GSH and APAP-SULF metabolites in MCD rats.
One of the most important observations in the current study was the altered disposition of APAP-GLUC metabolites in the rats with MCD-induced NASH. The marked reduction in the biliary concentration of APAP-GLUC was accompanied by a concurrent increase in its plasma and urine concentrations. These were in the range of those observed following pretreatment of the same strain of rats with various Mrp3-inducing compounds, including phenobarbital (Brouwer and Jones, 1990b; Slitt et al., 2003a; Xiong et al., 2002a) . In hepatocytes of normal rat liver, Mrp3 protein is expressed at much lower levels than Mrp2. Thus, although Mrp3 has a much higher affinity for APAP-GLUC, this metabolite is normally excreted predominantly into bile in rats (Brouwer and Jones, 1990a; Gregus et al., 1990) .
However, in the livers of rats with MCD-induced NASH, the expression levels of Mrp2 and Mrp3 appear to have become relatively equal, likely resulting in competition for the APAP-GLUC substrate. It therefore follows that the apparent shift from biliary to urinary excretion is most likely due to (1) the increased Mrp3 protein levels in liver and (2) the higher affinity of Mrp3 for the APAP-GLUC metabolite.
This article has not been copyedited and formatted. The final version may differ from this version. The concentration of APAP-SULF in bile was significantly lower in MCD rats compared to the control throughout the entire time-course. This result was unanticipated given the substantial up-regulation of both Mrp2 and Bcrp, which are responsible for the canalicular excretion of APAP-SULF. However, the plasma concentration of APAP-SULF was also consistently lower in MCD rats, and although the decrease of APAP-SULF in MCD rat urine did not reach statistical significance, it too appears to be slightly lower than the control.
Therefore, it would seem that the differences in disposition may have resulted from a decrease in sulfotransferase expression, sulfotransferase activity, and/or the sulfotransferase cofactor 3'-phosphoadenosine-5'-phosphosulfate.
The concentration of APAP-GSH in bile was also decreased in MCD rats throughout the time-course. This result was also unforeseen, given the pronounced induction of Mrp2 protein levels. In contrast, the concentration of APAP-GSH derivatives APAP-CG/CYS and APAP-NAC in urine were not altered in MCD rats. These data indicate that sinusoidal efflux transporters responsible for the hepatovascular excretion of APAP-GSH and its derivatives were able to maintain this function in MCD rat livers. However, it is also clear that fewer APAP-GSH metabolites and derivatives were formed in MCD rat livers. This effect may be partly due to the reduction ex vivo in cytochrome P450-mediated bioactivation of APAP to the reactive NAPQI form (data not shown), which undergoes a spontaneous electrophilic reaction with GSH to form APAP-GSH.
Hepatic GSH levels were not altered in either model of NAFLD (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. The metabolic capacity of the kidneys to form derivatives of the APAP-GSH conjugate is also an important consideration in the case of APAP disposition.
Following efflux of APAP-GSH conjugates from the liver into the sinusoidal blood, they are rapidly degraded into APAP-CG, APAP-CYS and APAP-NAC by the kidneys (Moldeus, 1978) . Thus, only the degradation products of APAP-GSH, including APAP-CG, APAP-CYS and APAP-NAC, are normally detectable in the urine (Gregus et al., 1988a) . Mrp2, which is expressed in the brush border membrane of rat proximal tubule cells, is presumably responsible for the tubular secretion of these APAP-GSH derivatives (Schaub et al., 1997) . There were no alterations in the urinary excretion of the APAP-GSH derivatives. Bcrp and Mrp4
are also present at high levels in rat kidneys and appear to be important in the secretion of sulfate conjugates from proximal tubule cells (Jonker et al., 2002; Mizuno et al., 2004; Tanaka et al., 2005a) . In contrast, Mrp3 is expressed at the basolateral membrane of renal proximal tubule cells and may participate in efflux of APAP-GLUC into blood (Kuroda et al., 2004) . metabolism (Levy and Yamada, 1971; Slattery and Levy, 1979; Galinsky and Levy, 1981; Lohr et al., 1998; Vendemiale et al., 1996) .
In summary, we report that diet-induced models of simple fatty liver steatosis and NASH produce multiple changes in efflux transporter expression in rats.
Importantly concentrations of the drug to its target site, e.g. ezetimibe and morphine 6-glucuronide (Oswald et al., 2006b; Oswald et al., 2006a; Zelcer et al., 2005) .
Therefore, future studies should place greater emphasis on determining the role of drug transporters in pharmacokinetics and pharmacodynamics of drug therapy administered during NAFLD.
